Followers | 88 |
Posts | 8196 |
Boards Moderated | 0 |
Alias Born | 06/17/2013 |
Thursday, October 10, 2019 8:16:54 AM
NEWS 9/9/19
(re-posted for newbies)
Therapeutic Solutions International Reports NanoStilbene™ Protects the Immune System
from Cancer Chemotherapy
Newly Discovered Properties of NanoStilbene Potentially Allows Company to Address
$3.9 Billion Chemotherapy Induced Neutropenia Market
https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/80689184/therapeutic-solutions-international-reports-nanost
OCEANSIDE, CA -- September 9, 2019 -- InvestorsHub NewsWire -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today new data and the filing of a patent application covering the ability of NanoStilbene™ [1] and its active ingredient, pterostilbene, at accelerating recovery of blood cells after treatment with chemotherapy.
Neutropenia is an abnormally low number of neutrophils (a type of white blood cell) in the blood. Neutropenia, if severe, significantly increases the risk of life-threatening infection. Neutropenia is often a side effect of the treatment of cancer with chemotherapy or radiation therapy.
In animals treated with the chemotherapeutic agent 5-fluorouracil, recovery of white blood cells occurred significantly faster in animals that also received NanoStilbene™ as compared to animals that received a placebo. The results were replicated with other types of chemotherapy including high dose cyclophosphamide and busulfan.
"We have previously reported that NanoStilbene™ can synergize with low dose cyclophosphamide at increasing immune response and killing of cancer [2]" said Dr. James Veltmeyer, Chief Medical Officer of the Company. "This new data supports the possibility of using NanoStilbene™ in many cancer patients who are taking chemotherapy, in order to protect the patients from the side effects of chemotherapy. In many cases, patients receiving chemotherapy have reduced white blood cells, which causes various types of infectious disease."
Currently, drugs such as Neulasta™ and Neupogen™ are used for increasing white blood cells in cancer patients taking chemotherapy. Unfortunately, these drugs cannot be taken prophylactically, and are highly expensive. According to Fierce Pharma, Neulasta™ had sales of $3.8 billion in 2018 [3]. More importantly, NanoStilbene possesses direct cancer-inhibitory properties, meaning that potentially it not only prevents chemotherapy-associated side effects but also increases the activity of the chemotherapy to kill cancer.
"I am impressed by the wide spectrum activity of the NanoStilbene™ product. It is very rare to find a therapy that concurrently suppresses the growth of cancer, stimulates the immune system, and protects the bone marrow from chemotherapy-induced toxicity" said Dr. Feng Lin, Chief Scientific Officer of the Company. "Since NanoStilbene™ is already on the market as a nutraceutical, I anticipate it will rapidly be utilized by informed patients who are suffering from cancer."
NanoStilbene is a nanoemulsion of nanoparticle pterostilbene in the range of 75-100nm at a concentration of 200mg per milliliter. Nanoparticle therapeutics is an emerging treatment modality for cancer and other inflammatory disorders. The National Cancer Institute has recognized nanotechnology as an emerging field with the potential to revolutionize modern medicine for the detection, treatment, and prevention of cancer.
"This Company was founded not only to advance great science but more importantly, to help patients for which limited options exist. The development of NanoStilbene™, we believe, offers the potential of a new generation of non-toxic compounds that concurrently stimulate the immune system while suppressing cancer at the same time" said Timothy Dixon, President, and CEO of the Company.
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one's immune system. The Company's corporate website is www.therapeuticsolutionsint.com and e-commerce at www.youcanordernow.com.
[1] https://mynanostilbene.com/?page_id=159
[2] https://www.globenewswire.com/news-release/2019/07/29/1892915/0/en/NanoStilbene-Nutraceutical-Shown-to-Increase-Ability-of-Cyclophosphamide-Chemotherapy-to-Suppress-Cancer.html
[3] https://www.fiercepharma.com/special-report/9-neulasta
NEWS 9/3/19
Feng Lin, MD, Ph.D., Joins Therapeutic Solutions International as Chief Scientific Officer
Immuno-Oncology Nutraceutical Company Positions Itself for Expansion into FDA
http://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/80650612/feng-lin-md-ph-d-joins-therapeutic-solutions-i
NEWS 8/29/19
Therapeutic Solutions International, Inc. Reports Revenues Up 850% for Q2 and 850% for 1st 6 months
https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/80626982/therapeutic-solutions-international-inc-reports
NEWS 8/26/19
Therapeutic Solutions International Announces Positive Clinical Data Using NanoStilbene™ to Stimulate Immune System in Advanced Cancer Patients
Company Submits Results of Clinical Trial for Publication in Peer Reviewed Medical Journal
https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/80602113/therapeutic-solutions-international-announces-posi
NEWS 8/5/19
Therapeutic Solutions International Collaborates with Right to Try Foundation on Novel Means of Protecting Patients While Hyper-accelerating Drug Development
Company Plans to Advance its Phase I Cancer Immunotherapy StemVacs™ to US Patients
https://www.globenewswire.com/news-release/2019/08/05/1896899/0/en/Therapeutic-Solutions-International-Collaborates-with-Right-to-Try-Foundation-on-Novel-Means-of-Protecting-Patients-While-Hyper-accelerating-Drug-Development.html
NEWS 7/29/19
NanoStilbene™ Nutraceutical Shown to Increase Ability of Cyclophosphamide Chemotherapy to Suppress Cancer
Recent Data Supports Investigation of Commercially Available Product
as an Adjuvant to Chemotherapy for Cancer
https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/80417735/nanostilbene-8482-nutraceutical-shown-to-increas
NEWS 7/22/19
Therapeutic Solutions International Reports its NanoStilbene™ Nutraceutical Product Enhances Efficacy of FDA Cleared Cancer Immunotherapy in Animal Model of Cancer
New Data Supports Development of Patented Formulation of Blueberry Extract Pterostilbene as an Adjuvant to Immuno-Oncology Treatments
https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/80371866/therapeutic-solutions-international-reports-its-na
NEWS 7/15/19
Therapeutic Solutions International adds Nano Cannabidiol to NanoMyros for Inhibition of Microvesicle and Exosome Release in Prostate Cancer
https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/80328380/therapeutic-solutions-international-adds-nano-cann
NEWS 7/11/19
Therapeutic Solutions International Develops Adjuvant Technology to Enhance Prostate Cancer Suppressing Properties of NanoPSA
Company Reports Synergistic Activation of Anti-Cancer Protein NRF2 By Proprietary Combination Approach
https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/80311774/therapeutic-solutions-international-develops-adjuv
NEWS 7/8/19
Therapeutic Solutions International Develops Glucoraphanin + NanoStilbene Encapsulated product for reduction of Prostate Specific Antigen (PSA)
https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/80285424/therapeutic-solutions-international-develops-gluco
NEWS 7/1/19
Therapeutic Solutions International Obtains Exclusive License for Patented Clinical Stage Adult Stem Cell for Treatment of Military and Sports Brain Injuries
https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/80242706/therapeutic-solutions-international-obtains-exclus
NEWS 5/6/19
Therapeutic Solutions International Awards Distribution of NanoStilbene and Nano Cannabidiol in Mexico to Immun ET Laboratories, LLC.
NanoStilbene Shown to Enhance Anticancer Immunity in Cancer Patients through Modulation of Inflammatory Mediators
https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/79840011/therapeutic-solutions-international-awards-distrib
NEWS 2/19/19
Therapeutic Solutions International Continues to Refine NanoStilbene™ Formulation
NanoStilbene Shown to Reduce Tumor Necrosis Factor-a (TNF-a ) in Cancer Patients
https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/79295986/therapeutic-solutions-international-continues-to-r
TSOI News History 5/1/18 - 1/22/19
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146277441
Recent TSOI News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 10:03:21 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 07:15:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 07:12:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/21/2024 10:25:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 11:16:15 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/08/2024 05:15:25 AM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 02/06/2024 11:34:40 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 08:42:55 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 01/17/2024 11:15:01 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 01/04/2024 09:03:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/22/2023 07:44:34 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2023 05:39:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/16/2023 11:17:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/16/2023 11:13:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/13/2023 06:50:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/13/2023 05:44:55 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/21/2023 09:24:52 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/15/2023 11:10:01 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/07/2023 08:29:10 PM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM